PROM1 and prostate cancer: CD133 has been postulated to identify CSC populations in numerous solid tumor types including several forms of brain cancer [80], prostate cancer [81], colon cancer [82], lung cancer [83], hepatocellular carcinoma [84], and ovarian cancer [85, 86], with the first 3 cancers being the most studied.